Is Gentamicin Ototoxic to the Fetus?

Journal of Obstetrics and Gynaecology Canada

Volumn 29, Issue 2, 2007, Pages 140-145

  Kirkwood, Allison ^a   Harris, Connie ^a   Timar, Niki ^a   Koren, Gideon ^b  

^a VANCOUVER ISLAND HEALTH AUTHORITY   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Aminoglycoside; Deafness; Fetus; Gentamicin; Hearing disorders; Hearing impairment; Hearing loss; Neonate; Ototoxicity; Pregnancy

Indexed keywords

GENTAMICIN; ANTIINFECTIVE AGENT;

ANOXIA; APGAR SCORE; ARTICLE; AUDIOLOGY; CHORIOAMNIONITIS; FETAL WELL BEING; FETUS WASTAGE; GENETIC PREDISPOSITION; HEARING IMPAIRMENT; HEARING TEST; HUMAN; HYPERBILIRUBINEMIA; INTRAUTERINE INFECTION; LIVE BIRTH; LOW BIRTH WEIGHT; MENINGITIS; NEWBORN INTENSIVE CARE; OTOTOXICITY; PREMATURITY; PRENATAL DRUG EXPOSURE; PYELONEPHRITIS; SEPSIS; TREATMENT DURATION; TREATMENT INDICATION; CHEMICALLY INDUCED DISORDER; EAR DISEASE; FEMALE; FETUS DISEASE; NEWBORN; PREGNANCY; PREGNANCY COMPLICATION;

ANTI-BACTERIAL AGENTS; EAR DISEASES; FEMALE; FETAL DISEASES; GENTAMICINS; HUMANS; INFANT, NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

EID: 34547602993     PISSN: 17012163     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1701-2163(16)32381-7     Document Type: Article

References (23)

1. Hill J.B., Sheffield J.S., McIntire D.D., Wendel G.D. Acute pyelonephritis in pregnancy. Obstet Gynecol 2005, 105:18-23.
2. Delzell J.E., Lefevre M.L. Urinary tract infections during pregnancy. Am Fam Physician 2000, 61:713-721.
3. Newton E.R. Preterm labor, preterm rupture of membranes and chorioamnionitis. Clin Perinatol 2005, 32:571-600.
4. Locksmith G.J., Chin A., Vu T., Shatuuck K.E., Hankins G.D. High compared with standard gentamicin dosing for chorioamnionitis: A comparison of maternal and fetal serum drug levels. Obstet Gynecol 2005, 105:473-479.
5. The Sanford guide to antimicrobial therapy 2006, Antimicrobial Therapy, Inc, Sperryville,VA. 36. D.N. Gilbert, R.C. Moellering, G.M. Eliopoulos, M.A. Sande (Eds.).
6. Compendium of pharmaceuticals and specialities: the Canadian drug reference for health professionals 2003, Canadian Pharmacists Association, Ottawa, ON. C. Repchinsky (Ed.).
7. Micromedex Healthcare Series: Thomson Micromedex, Greenwood Village, CO. Version 5.1. Accessed March 2006.
8. Czeizel A.E., Rockenbauer M., Olsen J., Sorensen H.T. A teratological study of aminoglycoside antibiotic treatment during pregnancy. Scand J Infect Dis 2000, 32:309-313.
9. Canadian Adverse Drug Reaction Monitoring Program. Summary of Reported Adverse Reactions; Suspected Drug: Gentamicin SOC: Fetal Disorders. All reports received from January 1, 1965 to August 31, 2006. Available at: . Accessed September 21, 2006. http://www.hc-sc.gc.ca/dhp-mps/medeff/databasdon/index_e.html.
10. Sanchez Sainz-Trapaga, Gutierrez Fonseca R., Ibanez Ruiz C., Moro Serrano M. Relacion entre un caso de hipoacusia infantil grave y al empleo de gentamicina en la madre gestante. An Esp Pediatr 1998, 49:397-398.
11. Stavroulaki P., Apostolopoulos N., Segas J., Tsakanikos M., Adamopoulos G. Evoked otoacoustic emissions-an approach for monitoring cisplatin induced ototoxicity in children. Int J Pediatr Otorhinolaryngol 2001, 59:47-57.
12. Zemlin W.R. Speech and hearing science: anatomy and physiology 1988, 432. Prentice Hall, Englewood Cliffs, NJ. 3.
13. Mueller H., Killion M. An easy method for calculating the articulation index. The Hearing Journal 1990, 43:14-17.
14. Fausti S.A., Henry J.A., Schaffer H.I., Olson D.J., Frey R.H., McDonald W.J. High-frequency audiometric monitoring for early detection of aminoglycoside ototoxicity. J Infect Dis 1992, 165:1026-1032.
15. Handbook of clinical drug data 2002, 859-863. McGraw-Hill Medical Publishing Division, New York. 10. P.O. Anderson, J.E. Knoben, W.G. Troutman (Eds.).
16. Stavroulaki P., Apostolopoulos N., Dinopoulou D., Vossinakis I., Tsakanikos M., Douniadakis D. Otoacoustic emissions-an approach for monitoring aminoglycoside induced ototoxicity in children. Int J Pediatr Otorhinolaryngol 1999, 50:177-184.
17. Orlando M.S., Prieve B.A. Models for universal newborn hearing screening programs. Universal newborn hearing screening 1998, 50-66. Thieme, New York. L.G. Spivak (Ed.).
18. Kohelet D., Usher M., Arber E., Arlazoroff A., Goldberg M. Effect of gentamicin on the auditory brainstem evoked response in term infants: a preliminary report. Pediatr Res 1990, 28:232-234.
19. Meyer C., Witte J., Hildmann A., Hennecke K.-H., Schunck K.-U., Maul K., et al. Neonatal screening for hearing disorders in infants at risk: Incidence, risk factors, and follow-up. Pediatrics 1999, 104:900-904.
20. Joint Committee on Infant Hearing. Joint Committee on Infant Hearing 1994 Position Statement. Audiology Today 1995, 6:6-9.
21. Johnson J.L., White K.R., Widen J.E., Gravel J.S., Vohr B.R., James M., et al. A multisite study to examine the efficacy of the otoacoustic emission/automated auditory brainstem response newborn hearing screening protocol: introduction and overview of the study. Am J Audiol 2005, 4:178-185.
22. Kerschner J.E. Neonatal hearing screening: to do or not to do. Pediatr Clin N Am 2004, 51:725-736.
23. Kalinec G.M., Fernandez-Zapico M.E., Urrutia R., Esteban-Cruciani N., Chen S., Kalinec F. Pivotal role of Harakiri in the induction and prevention of gentamicin-induced hearing loss. Proc Natl Acad Sci U S A 2005, 102:16019-16024.